JP5785687B2 - 急性虚血性脳卒中を処置するためのテネクテプラーゼの使用 - Google Patents

急性虚血性脳卒中を処置するためのテネクテプラーゼの使用 Download PDF

Info

Publication number
JP5785687B2
JP5785687B2 JP2009526788A JP2009526788A JP5785687B2 JP 5785687 B2 JP5785687 B2 JP 5785687B2 JP 2009526788 A JP2009526788 A JP 2009526788A JP 2009526788 A JP2009526788 A JP 2009526788A JP 5785687 B2 JP5785687 B2 JP 5785687B2
Authority
JP
Japan
Prior art keywords
tenecteplase
dose
minutes
bolus
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009526788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502629A5 (cg-RX-API-DMAC10.html
JP2010502629A (ja
Inventor
ピーター キューブラー，
ピーター キューブラー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5785687(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2010502629A publication Critical patent/JP2010502629A/ja
Publication of JP2010502629A5 publication Critical patent/JP2010502629A5/ja
Application granted granted Critical
Publication of JP5785687B2 publication Critical patent/JP5785687B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2009526788A 2006-08-29 2007-08-01 急性虚血性脳卒中を処置するためのテネクテプラーゼの使用 Active JP5785687B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82386806P 2006-08-29 2006-08-29
US60/823,868 2006-08-29
PCT/US2007/074997 WO2008027687A2 (en) 2006-08-29 2007-08-01 Use of tenecteplase for treating acute ischemic stroke

Publications (3)

Publication Number Publication Date
JP2010502629A JP2010502629A (ja) 2010-01-28
JP2010502629A5 JP2010502629A5 (cg-RX-API-DMAC10.html) 2011-08-18
JP5785687B2 true JP5785687B2 (ja) 2015-09-30

Family

ID=38835003

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009526788A Active JP5785687B2 (ja) 2006-08-29 2007-08-01 急性虚血性脳卒中を処置するためのテネクテプラーゼの使用

Country Status (21)

Country Link
US (2) US20080107641A1 (cg-RX-API-DMAC10.html)
EP (1) EP2056856B1 (cg-RX-API-DMAC10.html)
JP (1) JP5785687B2 (cg-RX-API-DMAC10.html)
KR (1) KR20090045405A (cg-RX-API-DMAC10.html)
CN (1) CN101505785A (cg-RX-API-DMAC10.html)
AU (1) AU2007290277B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0716143A2 (cg-RX-API-DMAC10.html)
CA (1) CA2661012C (cg-RX-API-DMAC10.html)
CO (1) CO6150188A2 (cg-RX-API-DMAC10.html)
EA (1) EA015573B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP099178A (cg-RX-API-DMAC10.html)
IL (2) IL196987A (cg-RX-API-DMAC10.html)
MX (1) MX2009001918A (cg-RX-API-DMAC10.html)
MY (1) MY163119A (cg-RX-API-DMAC10.html)
NO (1) NO342302B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ574767A (cg-RX-API-DMAC10.html)
SG (3) SG10201501498VA (cg-RX-API-DMAC10.html)
TW (1) TWI439282B (cg-RX-API-DMAC10.html)
UA (1) UA97486C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008027687A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200900957B (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
UA95903C2 (ru) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
TWI439282B (zh) 2006-08-29 2014-06-01 Genentech Inc 以血栓溶解劑治療中風之方法
EP3483140A1 (en) 2007-04-13 2019-05-15 Diffusion Pharmaceuticals LLC Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
US9034007B2 (en) 2007-09-21 2015-05-19 Insera Therapeutics, Inc. Distal embolic protection devices with a variable thickness microguidewire and methods for their use
EP2384141A1 (en) * 2008-12-24 2011-11-09 Koninklijke Philips Electronics N.V. System, method and apparatus for cardiac intervention with mr stroke detection and treatment
KR101875843B1 (ko) 2009-06-22 2018-07-06 디퓨젼 파마슈티컬즈 엘엘씨 확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도
CA2772097C (en) * 2009-08-24 2019-04-30 Hough Ear Institute Methods for treating acute acoustic trauma
CN105287473A (zh) 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
EP2654770B1 (en) * 2010-12-23 2018-07-11 Gennova Biopharmaceuticals Ltd. Pharmaceutical compositions of tenecteplase
WO2014062888A1 (en) * 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
US8679150B1 (en) 2013-03-15 2014-03-25 Insera Therapeutics, Inc. Shape-set textile structure based mechanical thrombectomy methods
US8715314B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment measurement methods
CA2901443A1 (en) 2013-03-15 2014-09-25 Insera Therapeutics, Inc. Vascular treatment devices and methods
US8715315B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment systems
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders
DK3209767T3 (da) * 2014-10-21 2020-11-02 Gennova Biopharmaceuticals Ltd Hidtil ukendt oprensningsfremgangsmåde til isolering og kommerciel fremstilling af rekombinant tnk-tpa (tenecteplase)
EP3416568A4 (en) 2016-02-16 2019-10-16 Insera Therapeutics, Inc. SUCTION DEVICES AND ANCHORED FLOW REVERSING DEVICES
WO2017165667A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
US12458379B2 (en) * 2017-01-24 2025-11-04 Boston Scientific Scimed, Inc. Method for the treatment of thromboembolism
WO2018210860A1 (en) * 2017-05-16 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
WO2021158799A1 (en) * 2020-02-04 2021-08-12 The Regents Of The University Of Colorado, A Body Corporate Prophylactic uses of annexin a2
CA3171307A1 (en) * 2020-02-19 2021-08-26 Nono Inc. Combination treatment of stroke with plasmin-cleavable psd-95 inhibitor and reperfusion
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用
CN115487294A (zh) * 2022-07-12 2022-12-20 上海丰华天力通生物医药有限公司 替奈普酶在制备用于治疗轻型缺血性卒中的药物组合物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3559559B2 (ja) 1992-06-03 2004-09-02 ジェネンテク，インコーポレイテッド 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
JP2002173447A (ja) * 2000-09-29 2002-06-21 Yamanouchi Pharmaceut Co Ltd 脳塞栓症治療用医薬組成物
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20030180282A1 (en) * 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
TWI439282B (zh) 2006-08-29 2014-06-01 Genentech Inc 以血栓溶解劑治療中風之方法

Also Published As

Publication number Publication date
CN101505785A (zh) 2009-08-12
IL248176A0 (en) 2016-11-30
TW200817033A (en) 2008-04-16
CA2661012C (en) 2019-03-19
US9023346B2 (en) 2015-05-05
CO6150188A2 (es) 2010-04-20
US20120164157A1 (en) 2012-06-28
EP2056856A2 (en) 2009-05-13
KR20090045405A (ko) 2009-05-07
SG174753A1 (en) 2011-10-28
MX2009001918A (es) 2009-03-06
TWI439282B (zh) 2014-06-01
BRPI0716143A2 (pt) 2013-11-26
EA015573B1 (ru) 2011-10-31
IL196987A0 (en) 2011-08-01
WO2008027687A2 (en) 2008-03-06
AU2007290277A1 (en) 2008-03-06
WO2008027687A3 (en) 2008-05-22
SG10201501498VA (en) 2015-04-29
JP2010502629A (ja) 2010-01-28
ZA200900957B (en) 2010-05-26
AU2007290277B2 (en) 2013-04-11
ECSP099178A (es) 2009-06-30
IL196987A (en) 2016-10-31
MY163119A (en) 2017-08-15
US20080107641A1 (en) 2008-05-08
CA2661012A1 (en) 2008-03-06
SG10201804944XA (en) 2018-07-30
UA97486C2 (ru) 2012-02-27
NO342302B1 (no) 2018-04-30
HK1131054A1 (en) 2010-01-15
NO20091296L (no) 2009-05-28
EP2056856B1 (en) 2015-01-14
EA200970237A1 (ru) 2009-08-28
NZ574767A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
AU2007290277B2 (en) Use of tenecteplase for treating acute ischemic stroke
EP3395359A1 (en) Method for preventing or treating acute thrombosis and chronic thrombosis
MX2007013877A (es) Metodo no quirurgico para prevenir o reducir el indice de progresion de retinopatia diabetica no proliferativa y tratamiento de otras condiciones oculares.
ONCEL et al. Tissue plasminogen activator in the treatment of experimental retinal vein occlusion
Phillips et al. The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model
US20190231856A1 (en) Compositions and methods for treating intracerebral hemorrhage
Marè et al. Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke
Turcasso et al. Tenecteplase for treatment of acute myocardial infarction
EP2501399A2 (en) Treatment of acute ischemic stroke or intracranial bleeding with tpa and carbamylated erythropoietin
HK1131054B (en) Use of tenecteplase for treating acute ischemic stroke
Verma et al. Pharmacological strategies for stroke intervention: assessment of pathophysiological relevance and clinical trials
Brott Reopening occluded cerebral arteries
HK40105798A (en) Pharmaceutical composition for use in treating cerebral infarction
Hoang et al. The efficacy and safety of tissue plasminogen activator in acute ischemic strokes
JP2022551373A (ja) 三環式誘導体を用いた脳卒中の治療方法
CN114984197A (zh) 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用
Diaz-Ricart Desmoteplase
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
WO2007134813A2 (en) Use of desmodus salivary plasminogen activator (dspa) for treating venous thromboembolism
FAST What happens during a stroke
CN113301907A (zh) 用于治疗和/或改善伴有凝血障碍的败血症的药物
JP2008507561A (ja) 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140716

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140814

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150727

R150 Certificate of patent or registration of utility model

Ref document number: 5785687

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250